Loading...

Henry Chambers, III, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Phone628-206-5437
vCardDownload vCard
    Other Positions
    Title(s)Chief, Division of Infectious Diseases, SFGH

    Title(s)Director, Clinical Research Services, CTSI


    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine
    Vanderbilt UniversityM.D.School of Medicine
    Centre College Kentucky B.A.

    Collapse Overview 
    Collapse Overview
    Dr. Chambers clinical and research interests are antimicrobial drug resistance, staphylococcal infections, experimental therapeutics, and epidemiology and pathogenesis of disease caused by Staphylococcus aureus. He is editor for the Sanford Guide to Antimicrobial Therapy and he has over 200 original publications and textbook chapters in the areas of drug resistance, endocarditis, bacterial infections, and staphylococcal diseases.

    Dr. Chambers received his BA from Centre College in Kentucky and is a graduate of the Vanderbilt University School of Medicine. He trained in Internal Medicine and Infectious Diseases at the University of California San Francisco. Dr. Chambers has been a member of the medical faculty of the UCSF since 1983 where he currently is Professor of Medicine, Medical Director of Clinical Research Services for CTSI. He is an editor for Antimicrobial Agents and Chemotherapy, a reviewer for numerous medical publications, a peer reviewer for NIH study sections.

    Collapse Research 
    Collapse Research Activities and Funding
    Antibacterial Resistance Leadership Group (ARLG)
    NIH/NIAID UM1AI104681Jun 1, 2013 - Nov 30, 2019
    Role: Co-Principal Investigator
    Novel Mechanisms of Beta-lactam Resistance in Staph Aureus
    NIH/NIAID R01AI100291Aug 1, 2012 - Dec 31, 2022
    Role: Principal Investigator
    Novel Mechanisms of Beta-lactam Resistance in Staph Aureus
    NIH/NIAID R56AI100291Aug 1, 2012 - Jul 31, 2018
    Role: Principal Investigator
    Genetic Basis of Virulence of Community MRSA Clone USA300
    NIH/NIAID R01AI070289Apr 1, 2008 - Mar 31, 2012
    Role: Principal Investigator
    Gordon Research Conference on Staphylococcal Diseases
    NIH/NIAID R13AI050556Jul 1, 2001 - Jun 30, 2002
    Role: Principal Investigator
    Biology of Infectious Diseases Training Program
    NIH/NIAID T32AI007641Aug 1, 2000 - Aug 31, 2022
    Role: Principal Investigator
    PENICILLIN INTERACTIVE PROTEINS OF STAPHYLOCOCCUS AUREUS
    NIH/NIAID R01AI046610Feb 1, 2000 - Jan 31, 2005
    Role: Principal Investigator
    GORDON CONFERENCE ON STAPHYLOCOCCAL DISEASES
    NIH/NIAID R13AI043943May 1, 1999 - Apr 30, 2000
    Role: Principal Investigator
    VANCOMYCIN-RESISTANT STAPHYLOCOCCUS AUREUS
    NIH/NIAID R03AI043959Apr 1, 1999 - Mar 31, 2002
    Role: Principal Investigator
    PENICILLIN BINDING PROTEINS OF STAPHYLOCOCCUS AUREUS
    NIH/NIAID R21AI032496Sep 30, 1996 - Sep 29, 1999
    Role: Principal Investigator
    DEVELOPMENT OF DRUGS FOR TREATING TUBERCULOSIS
    NIH/NIAID R01AI033702Sep 30, 1992 - Aug 31, 1997
    Role: Principal Investigator
    METHICILLIN RESISTANCE OF STAPHYLOCOCCUS AUREUS
    NIH/NIAID R29AI027406Dec 1, 1988 - Nov 30, 1993
    Role: Principal Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000083Oct 1, 1974 - Nov 30, 2007
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Kalil AC, Holubar M, Deresinski S, Chambers HF. Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia? Antimicrob Agents Chemother. 2019 Nov; 63(11). PMID: 31640977.
      View in: PubMed
    2. Ersoy SC, Abdelhady W, Li L, Chambers HF, Xiong YQ, Bayer AS. Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to ß-Lactam Antibiotics. Antimicrob Agents Chemother. 2019 Jul; 63(7). PMID: 31010857.
      View in: PubMed
    3. Doernberg SB, Tran TTT, Tong SYC, Paul M, Yahav D, Davis JS, Leibovici L, Boucher HW, Corey GR, Cosgrove SE, Chambers HF, Fowler VG, Evans SR, Holland TL. Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection. Clin Infect Dis. 2019 May 02; 68(10):1691-1698. PMID: 30321315.
      View in: PubMed
    4. Guimaraes AO, Cao Y, Hong K, Mayba O, Peck MC, Gutierrez J, Ruffin F, Carrasco-Triguero M, Dinoso JB, Clemenzi-Allen A, Koss CA, Maskarinec SA, Chambers HF, Fowler VG, Baruch A, Rosenberger CM. A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection. Clin Infect Dis. 2019 Apr 24; 68(9):1502-1511. PMID: 30165412.
      View in: PubMed
    5. Chambers HF. Omadacycline - The Newest Tetracycline. N Engl J Med. 2019 02 07; 380(6):588-589. PMID: 30726683.
      View in: PubMed
    6. Alexander JAN, Chatterjee SS, Hamilton SM, Eltis LD, Chambers HF, Strynadka NCJ. Structural and kinetic analyses of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance in Staphylococcus aureus. J Biol Chem. 2018 12 21; 293(51):19854-19865. PMID: 30366985.
      View in: PubMed
    7. Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma PD, Chambers HF. Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting. Clin Infect Dis. 2018 09 28; 67(8):1168-1174. PMID: 29590355.
      View in: PubMed
    8. da Costa TM, de Oliveira CR, Chambers HF, Chatterjee SS. PBP4: A New Perspective on Staphylococcus aureus ß-Lactam Resistance. Microorganisms. 2018 06 22; 6(3). PMID: 29932109.
      View in: PubMed
    9. Basuino L, Jousselin A, Alexander JAN, Strynadka NCJ, Pinho MG, Chambers HF, Chatterjee SS. PBP4 activity and its overexpression are necessary for PBP4-mediated high-level ß-lactam resistance. J Antimicrob Chemother. 2018 05 01; 73(5):1177-1180. PMID: 29360990.
      View in: PubMed
    10. Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku T, Ochiai T, Komatsu N, Chambers HF. Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2017 11; 61(11). PMID: 28827421.
      View in: PubMed
    11. Chatterjee SS, Chen L, Gilbert A, da Costa TM, Nair V, Datta SK, Kreiswirth BN, Chambers HF. PBP4 Mediates ß-Lactam Resistance by Altered Function. Antimicrob Agents Chemother. 2017 11; 61(11). PMID: 28807923.
      View in: PubMed
    12. Doernberg SB, Chambers HF. Antimicrobial Stewardship Approaches in the Intensive Care Unit. Infect Dis Clin North Am. 2017 09; 31(3):513-534. PMID: 28687210.
      View in: PubMed
    13. Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, Kumar N, Downing M, Pettibone S, Hoagland R, Eells SJ, Boyle MG, Parker TC, Chambers HF. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. N Engl J Med. 2017 06 29; 376(26):2545-2555. PMID: 28657870.
      View in: PubMed
    14. Hamilton SM, Alexander JAN, Choo EJ, Basuino L, da Costa TM, Severin A, Chung M, Aedo S, Strynadka NCJ, Tomasz A, Chatterjee SS, Chambers HF. High-Level Resistance of Staphylococcus aureus to ß-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4). Antimicrob Agents Chemother. 2017 06; 61(6). PMID: 28373193.
      View in: PubMed
    15. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. Can Ceftazidime-Avibactam and Aztreonam Overcome ß-Lactam Resistance Conferred by Metallo-ß-Lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017 04; 61(4). PMID: 28167541.
      View in: PubMed
    16. Chambers HF, Cross HR, Evans SR, Kreiswirth BN, Fowler VG. The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress. Clin Infect Dis. 2017 Mar 15; 64(suppl_1):S3-S7. PMID: 28350896.
      View in: PubMed
    17. Nigo M, Diaz L, Carvajal LP, Tran TT, Rios R, Panesso D, Garavito JD, Miller WR, Wanger A, Weinstock G, Munita JM, Arias CA, Chambers HF. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis. Antimicrob Agents Chemother. 2017 03; 61(3). PMID: 28232309.
      View in: PubMed
    18. Choo EJ, Chambers HF. Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Infect Chemother. 2016 12; 48(4):267-273. PMID: 28032484.
      View in: PubMed
    19. Diep BA, Le VT, Badiou C, Le HN, Pinheiro MG, Duong AH, Wang X, Dip EC, Aguiar-Alves F, Basuino L, Marbach H, Mai TT, Sarda MN, Kajikawa O, Matute-Bello G, Tkaczyk C, Rasigade JP, Sellman BR, Chambers HF, Lina G. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med. 2016 09 21; 8(357):357ra124. PMID: 27655850.
      View in: PubMed
    20. Baxi SM, Clemenzi-Allen A, Gahbauer A, Deck D, Imp B, Vittinghoff E, Chambers HF, Doernberg S. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2016 09; 60(9):5276-84. PMID: 27324762.
      View in: PubMed
    21. Pollett S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambers HF. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center. Antimicrob Agents Chemother. 2016 08; 60(8):4684-9. PMID: 27216053.
      View in: PubMed
    22. Chambers HF, Basuino L, Hamilton SM, Choo EJ, Moise P. Daptomycin-ß-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis. Antimicrob Agents Chemother. 2016 07; 60(7):3976-9. PMID: 27090173.
      View in: PubMed
    23. Chan LC, Gilbert A, Basuino L, da Costa TM, Hamilton SM, Dos Santos KR, Chambers HF, Chatterjee SS. PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus. Antimicrob Agents Chemother. 2016 07; 60(7):3934-41. PMID: 27067335.
      View in: PubMed
    24. Greninger AL, Chatterjee SS, Chan LC, Hamilton SM, Chambers HF, Chiu CY. Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance. PLoS One. 2016; 11(2):e0149541. PMID: 26890675.
      View in: PubMed
    25. Chan LC, Basuino L, Dip EC, Chambers HF. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2015; 59(6):3252-6. PMID: 25801564.
      View in: PubMed
    26. Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med. 2015 Mar 19; 372(12):1093-103. PMID: 25785967.
      View in: PubMed
    27. Chan LC, Basuino L, Diep B, Hamilton S, Chatterjee SS, Chambers HF. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2015 May; 59(5):2960-3. PMID: 25753637.
      View in: PubMed
    28. Chambers HF. Probability of eradication using vancomycin alone or in combination for methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2014 Dec; 58(12):7617. PMID: 25392536.
      View in: PubMed
    29. Chambers HF. Pharmacology and the treatment of complicated skin and skin-structure infections. N Engl J Med. 2014 Jun 05; 370(23):2238-9. PMID: 24897088.
      View in: PubMed
    30. Date SV, Modrusan Z, Lawrence M, Morisaki JH, Toy K, Shah IM, Kim J, Park S, Xu M, Basuino L, Chan L, Zeitschel D, Chambers HF, Tan MW, Brown EJ, Diep BA, Hazenbos WL. Global gene expression of methicillin-resistant Staphylococcus aureus USA300 during human and mouse infection. J Infect Dis. 2014 May 15; 209(10):1542-50. PMID: 24286981.
      View in: PubMed
    31. Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, Sellman B, Badiou C, Lina G, Chambers HF. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis. 2013 Jul; 208(1):75-82. PMID: 23532096.
      View in: PubMed
    32. Hsiang MS, Shiau R, Nadle J, Chan L, Lee B, Chambers HF, Pan E. Epidemiologic Similarities in Pediatric Community-Associated Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus in the San Francisco Bay Area. J Pediatric Infect Dis Soc. 2012 Sep; 1(3):200-11. PMID: 23687577.
      View in: PubMed
    33. Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, Mai TT, Vo NH, Dang DN, Phan TH, Basuino L, Perdreau-Remington F, Chambers HF, Diep BA. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2012 Sep; 55(6):781-8. PMID: 22670044.
      View in: PubMed
    34. Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis. 2012 Sep; 55(5):615-20. PMID: 22563022.
      View in: PubMed
    35. Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM, Chambers HF, Tomasz A. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog. 2012 Feb; 8(2):e1002505. PMID: 22319446.
      View in: PubMed
    36. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011 Feb 01; 52(3):285-92. PMID: 21217178.
      View in: PubMed
    37. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 01; 52(3):e18-55. PMID: 21208910.
      View in: PubMed
    38. Banerjee R, Gretes M, Harlem C, Basuino L, Chambers HF. A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level ß-lactam resistance contains mutations in three genes. Antimicrob Agents Chemother. 2010 Nov; 54(11):4900-2. PMID: 20805396.
      View in: PubMed
    39. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A. 2010 Mar 23; 107(12):5587-92. PMID: 20231457.
      View in: PubMed
    40. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. Lancet. 2010 May 01; 375(9725):1557-68. PMID: 20206987.
      View in: PubMed
    41. Mendes RE, Sader HS, Deshpande LM, Diep BA, Chambers HF, Jones RN. Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid. J Clin Microbiol. 2010 Feb; 48(2):568-74. PMID: 19940054.
      View in: PubMed
    42. Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010 Feb; 54(2):610-3. PMID: 19917746.
      View in: PubMed
    43. DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest. 2009 Sep; 119(9):2464-74. PMID: 19729844.
      View in: PubMed
    44. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009 Sep; 7(9):629-41. PMID: 19680247.
      View in: PubMed
    45. Winston L, Chambers H. Coming home with MRSA. Arch Intern Med. 2009 Aug 10; 169(15):1379-80. PMID: 19667300.
      View in: PubMed
    46. Schwartz BS, Graber CJ, Diep BA, Basuino L, Perdreau-Remington F, Chambers HF. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Clin Infect Dis. 2009 May 15; 48(10):1483-4. PMID: 19374563.
      View in: PubMed
    47. Tattevin P, Basuino L, Chambers HF. Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response. Res Microbiol. 2009 Apr; 160(3):187-92. PMID: 19366630.
      View in: PubMed
    48. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y, Otto M. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A. 2009 Apr 07; 106(14):5883-8. PMID: 19293374.
      View in: PubMed
    49. Cosgrove SE, Vigliani GA, Fowler VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009 Mar 15; 48(6):713-21. PMID: 19207079.
      View in: PubMed
    50. Chambers HF, Basuino L, Diep BA, Steenbergen J, Zhang S, Tattevin P, Alder J. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrob Agents Chemother. 2009 Apr; 53(4):1463-7. PMID: 19171803.
      View in: PubMed
    51. Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. J Acquir Immune Defic Syndr. 2008 Oct 01; 49(2):231-3. PMID: 18820536.
      View in: PubMed
    52. Diep BA, Palazzolo-Ballance AM, Tattevin P, Basuino L, Braughton KR, Whitney AR, Chen L, Kreiswirth BN, Otto M, DeLeo FR, Chambers HF. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One. 2008 Sep 12; 3(9):e3198. PMID: 18787708.
      View in: PubMed
    53. Liu C, Graber CJ, Karr M, Diep BA, Basuino L, Schwartz BS, Enright MC, O'Hanlon SJ, Thomas JC, Perdreau-Remington F, Gordon S, Gunthorpe H, Jacobs R, Jensen P, Leoung G, Rumack JS, Chambers HF. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis. 2008 Jun 01; 46(11):1637-46. PMID: 18433335.
      View in: PubMed
    54. Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages SA, Jones A, Palazzolo-Ballance AM, Perdreau-Remington F, Sensabaugh GF, DeLeo FR, Chambers HF. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis. 2008 Jun 01; 197(11):1523-30. PMID: 18700257.
      View in: PubMed
    55. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008 Jun 01; 46 Suppl 5:S368-77. PMID: 18462092.
      View in: PubMed
    56. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008 Jun; 52(6):2089-96. PMID: 18378703.
      View in: PubMed
    57. David MZ, Siegel JD, Chambers HF, Daum RS. Determining whether methicillin-resistant Staphylococcus aureus is associated with health care. JAMA. 2008 Feb 06; 299(5):519; author reply 519-20. PMID: 18252879.
      View in: PubMed
    58. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008 Feb 19; 148(4):249-57. PMID: 18283202.
      View in: PubMed
    59. Rajendran PM, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P, Harris H. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007 Nov; 51(11):4044-8. PMID: 17846141.
      View in: PubMed
    60. Chambers HF, Hegde SS. Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? Expert Rev Anti Infect Ther. 2007 Jun; 5(3):333-5. PMID: 17547497.
      View in: PubMed
    61. Graber CJ, Wong MK, Carleton HA, Perdreau-Remington F, Haller BL, Chambers HF. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis. 2007 Mar; 13(3):491-3. PMID: 17552110.
      View in: PubMed
    62. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 Aug 17; 355(7):653-65. PMID: 16914701.
      View in: PubMed
    63. Rutar T, Chambers HF, Crawford JB, Perdreau-Remington F, Zwick OM, Karr M, Diehn JJ, Cockerham KP. Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus. Ophthalmology. 2006 Aug; 113(8):1455-62. PMID: 16766029.
      View in: PubMed
    64. Seeley EJ, Chambers HF. Diabetic ketoacidosis precipitated by Staphylococcus aureus abscess and bacteremia due to acupuncture: case report and review of the literature. Clin Infect Dis. 2006 Jul 01; 43(1):e6-8. PMID: 16758409.
      View in: PubMed
    65. Chambers HF. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin Microbiol Infect. 2006 Apr; 12 Suppl 2:17-22. PMID: 16524424.
      View in: PubMed
    66. Madrigal AG, Basuino L, Chambers HF. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2005 Aug; 49(8):3163-5. PMID: 16048918.
      View in: PubMed
    67. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother. 2005 Jul; 49(7):2816-21. PMID: 15980354.
      View in: PubMed
    68. Eguia JM, Liu C, Moore M, Wrone EM, Pont J, Gerberding JL, Chambers HF. Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. Clin Infect Dis. 2005 Jun 01; 40(11):1617-24. PMID: 15889359.
      View in: PubMed
    69. Siboo IR, Chambers HF, Sullam PM. Role of SraP, a Serine-Rich Surface Protein of Staphylococcus aureus, in binding to human platelets. Infect Immun. 2005 Apr; 73(4):2273-80. PMID: 15784571.
      View in: PubMed
    70. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2005 Mar; 49(3):884-8. PMID: 15728879.
      View in: PubMed
    71. Winston LG, Charlebois ED, Pang S, Bangsberg DR, Perdreau-Remington F, Chambers HF. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. Am J Infect Control. 2004 Dec; 32(8):462-9. PMID: 15573053.
      View in: PubMed
    72. Young DM, Harris HW, Charlebois ED, Chambers H, Campbell A, Perdreau-Remington F, Lee C, Mankani M, Mackersie R, Schecter WP. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg. 2004 Sep; 139(9):947-51; discussion 951-3. PMID: 15381611.
      View in: PubMed
    73. Wilke MS, Hills TL, Zhang HZ, Chambers HF, Strynadka NC. Crystal structures of the Apo and penicillin-acylated forms of the BlaR1 beta-lactam sensor of Staphylococcus aureus. J Biol Chem. 2004 Nov 05; 279(45):47278-87. PMID: 15322076.
      View in: PubMed
    74. Charlebois ED, Perdreau-Remington F, Kreiswirth B, Bangsberg DR, Ciccarone D, Diep BA, Ng VL, Chansky K, Edlin BR, Edlin B, Chambers HF. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2004 Jul 01; 39(1):47-54. PMID: 15206052.
      View in: PubMed
    75. Winston LG, Pang S, Haller BL, Wong M, Chambers HF, Perdreau-Remington F. API 20 strep identification system may incorrectly speciate enterococci with low level resistance to vancomycin. Diagn Microbiol Infect Dis. 2004 Apr; 48(4):287-8. PMID: 15062923.
      View in: PubMed
    76. Katayama Y, Zhang HZ, Chambers HF. PBP 2a mutations producing very-high-level resistance to beta-lactams. Antimicrob Agents Chemother. 2004 Feb; 48(2):453-9. PMID: 14742194.
      View in: PubMed
    77. Eguia JM, Chambers HF. Community-acquired Methicillin-resistant Staphylococcus aureus: Epidemiology and Potential Virulence Factors. Curr Infect Dis Rep. 2003 Dec; 5(6):459-466. PMID: 14642185.
      View in: PubMed
    78. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003 Oct; 47(10):3040-5. PMID: 14506006.
      View in: PubMed
    79. Katayama Y, Zhang HZ, Hong D, Chambers HF. Jumping the barrier to beta-lactam resistance in Staphylococcus aureus. J Bacteriol. 2003 Sep; 185(18):5465-72. PMID: 12949098.
      View in: PubMed
    80. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother. 2003 Apr; 47(4):1262-6. PMID: 12654656.
      View in: PubMed
    81. Chambers HF. Solving staphylococcal resistance to beta-lactams. Trends Microbiol. 2003 Apr; 11(4):145-8. PMID: 12706985.
      View in: PubMed
    82. Eguia JM, Chambers HF. Methicillin-resistant staphylococci and their treatment in the intensive care unit. Semin Respir Crit Care Med. 2003 Feb; 24(1):37-48. PMID: 16088523.
      View in: PubMed
    83. Katayama Y, Zhang HZ, Chambers HF. Effect of disruption of Staphylococcus aureus PBP4 gene on resistance to beta-lactam antibiotics. Microb Drug Resist. 2003; 9(4):329-36. PMID: 15000739.
      View in: PubMed
    84. Winston LG, Bangsberg DR, Chambers HF, Felt SC, Rosen JI, Charlebois ED, Wong M, Steele L, Gerberding JL, Perdreau-Remington F. Epidemiology of vancomycin-resistant Enterococcus faecium under a selective isolation policy at an urban county hospital. Am J Infect Control. 2002 Nov; 30(7):400-6. PMID: 12410216.
      View in: PubMed
    85. Charlebois ED, Bangsberg DR, Moss NJ, Moore MR, Moss AR, Chambers HF, Perdreau-Remington F. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis. 2002 Feb 15; 34(4):425-33. PMID: 11797167.
      View in: PubMed
    86. Kanaya AM, Glidden DV, Chambers HF. Identifying pulmonary tuberculosis in patients with negative sputum smear results. Chest. 2001 Aug; 120(2):349-55. PMID: 11502628.
      View in: PubMed
    87. Zhang HZ, Hackbarth CJ, Chansky KM, Chambers HF. A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci. Science. 2001 Mar 09; 291(5510):1962-5. PMID: 11239156.
      View in: PubMed
    88. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis. 2001 Mar-Apr; 7(2):178-82. PMID: 11294701.
      View in: PubMed
    89. Chambers HF. Methicillin-resistant Staphylococcus aureus. Mechanisms of resistance and implications for treatment. Postgrad Med. 2001 Feb; 109(2 Suppl):43-50. PMID: 19667557.
      View in: PubMed
    90. Chambers HF, Xiang Q, Chow LL, Hackbarth C. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus. Antimicrob Agents Chemother. 1999 Nov; 43(11):2742-6. PMID: 10543757.
      View in: PubMed
    91. Kim YS, Liu Q, Chow LL, Chambers HF, Täuber MG. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1998 Dec; 42(12):3325-7. PMID: 9835540.
      View in: PubMed
    92. Sheppard DC, Chambers HF. Suppurative parotitis. West J Med. 1998 Aug; 169(2):116-7. PMID: 9735697.
      View in: PubMed
    93. Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis. 1998 Apr; 26(4):874-7. PMID: 9564467.
      View in: PubMed
    94. Hackbarth CJ, Unsal I, Chambers HF. Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother. 1997 May; 41(5):1182-5. PMID: 9145897.
      View in: PubMed
    95. Sweet-Cordero EA, Chambers HF, Cicero-Sabido R, Santos-Preciado JI. Burden of Mycobacterium tuberculosis in sputum samples can be reliably determined using a quantitative, non-radioactive polymerase chain reaction assay. Tuber Lung Dis. 1996 Dec; 77(6):496-501. PMID: 9039441.
      View in: PubMed
    96. Kocagöz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother. 1996 Aug; 40(8):1768-74. PMID: 8843279.
      View in: PubMed
    97. Frank U, Chambers HF. Treatment of Staphylococcus aureus catheter-related infection and infective endocarditis with granulocyte colony-stimulating factor in the experimental rabbit model. Antimicrob Agents Chemother. 1996 May; 40(5):1308-10. PMID: 8723492.
      View in: PubMed
    98. Lee BL, Täuber MG, Sadler B, Goldstein D, Chambers HF. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin Pharmacol Ther. 1996 Jan; 59(1):14-21. PMID: 8549029.
      View in: PubMed
    99. Chambers HF, Moreau D, Yajko D, Miick C, Wagner C, Hackbarth C, Kocagöz S, Rosenberg E, Hadley WK, Nikaido H. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob Agents Chemother. 1995 Dec; 39(12):2620-4. PMID: 8592990.
      View in: PubMed
    100. Yajko DM, Wagner C, Tevere VJ, Kocagöz T, Hadley WK, Chambers HF. Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay. J Clin Microbiol. 1995 Jul; 33(7):1944-7. PMID: 7665679.
      View in: PubMed
    101. Chambers HF, Kartalija M, Sande M. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J Infect Dis. 1995 Apr; 171(4):897-902. PMID: 7706817.
      View in: PubMed
    102. Chambers HF. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a. Antimicrob Agents Chemother. 1995 Feb; 39(2):462-6. PMID: 7726516.
      View in: PubMed
    103. Hackbarth CJ, Kocagoz T, Kocagoz S, Chambers HF. Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance. Antimicrob Agents Chemother. 1995 Jan; 39(1):103-6. PMID: 7695289.
      View in: PubMed
    104. Hackbarth CJ, Miick C, Chambers HF. Altered production of penicillin-binding protein 2a can affect phenotypic expression of methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Nov; 38(11):2568-71. PMID: 7872749.
      View in: PubMed
    105. Chambers HF, Fournier MA. Efficacy of cefoperazone in combination with sulbactam in experimental Staphylococcus aureus endocarditis in rabbits. J Antimicrob Chemother. 1993 Sep; 32(3):453-8. PMID: 8262867.
      View in: PubMed
    106. Chambers HF. Detection of methicillin-resistant staphylococci. Infect Dis Clin North Am. 1993 Jun; 7(2):425-33. PMID: 8345177.
      View in: PubMed
    107. Hackbarth CJ, Chambers HF. blaI and blaR1 regulate beta-lactamase and PBP 2a production in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1993 May; 37(5):1144-9. PMID: 8517704.
      View in: PubMed
    108. Chambers HF. Short-course combination and oral therapies of Staphylococcus aureus endocarditis. Infect Dis Clin North Am. 1993 Mar; 7(1):69-80. PMID: 8463654.
      View in: PubMed
    109. Chambers HF. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1992 Jul; 30 Suppl A:117-22. PMID: 1399943.
      View in: PubMed
    110. Chambers HF, Miick C. Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides. Antimicrob Agents Chemother. 1992 Mar; 36(3):656-61. PMID: 1622180.
      View in: PubMed
    111. Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 1991 Dec; 35(12):2505-8. PMID: 1667253.
      View in: PubMed
    112. Gerberding JL, Miick C, Liu HH, Chambers HF. Comparison of conventional susceptibility tests with direct detection of penicillin-binding protein 2a in borderline oxacillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1991 Dec; 35(12):2574-9. PMID: 1810191.
      View in: PubMed
    113. Barg N, Chambers H, Kernodle D. Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the hyperproduction of beta-lactamase. Antimicrob Agents Chemother. 1991 Oct; 35(10):1975-9. PMID: 1759816.
      View in: PubMed
    114. Chambers HF. Treatment of infection and colonization caused by methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 1991 Jan; 12(1):29-35. PMID: 1847961.
      View in: PubMed
    115. Chambers HF, Sachdeva M, Kennedy S. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Sep; 162(3):705-10. PMID: 2387996.
      View in: PubMed
    116. Stratton CW, Gelfand MS, Gerberding JL, Chambers HF. Characterization of mechanisms of resistance to beta-lactam antibiotics in methicillin-resistant strains of Staphylococcus saprophyticus. Antimicrob Agents Chemother. 1990 Sep; 34(9):1780-2. PMID: 2285290.
      View in: PubMed
    117. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990 Jun; 34(6):1227-31. PMID: 2393284.
      View in: PubMed
    118. Chambers HF, Sachdeva M. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Jun; 161(6):1170-6. PMID: 2345297.
      View in: PubMed
    119. Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother. 1990 Apr; 34(4):510-4. PMID: 2140496.
      View in: PubMed
    120. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet. 1989 Nov 04; 2(8671):1071-3. PMID: 2572799.
      View in: PubMed
    121. Padula A, Chambers HF. Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits. Antimicrob Agents Chemother. 1989 Oct; 33(10):1822-3. PMID: 2686548.
      View in: PubMed
    122. Kennedy S, Chambers HF. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob Agents Chemother. 1989 Sep; 33(9):1522-5. PMID: 2554799.
      View in: PubMed
    123. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: detection methods and treatment of infections. Antimicrob Agents Chemother. 1989 Jul; 33(7):995-9. PMID: 2675760.
      View in: PubMed
    124. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: genetics and mechanisms of resistance. Antimicrob Agents Chemother. 1989 Jul; 33(7):991-4. PMID: 2675759.
      View in: PubMed
    125. Chambers HF, Archer G, Matsuhashi M. Low-level methicillin resistance in strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1989 Apr; 33(4):424-8. PMID: 2729937.
      View in: PubMed
    126. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med. 1988 Oct 15; 109(8):619-24. PMID: 3421575.
      View in: PubMed
    127. Chambers HF. Methicillin-resistant staphylococci. Clin Microbiol Rev. 1988 Apr; 1(2):173-86. PMID: 3069195.
      View in: PubMed
    128. Chambers HF. Coagulase-negative staphylococci resistant to beta-lactam antibiotics in vivo produce penicillin-binding protein 2a. Antimicrob Agents Chemother. 1987 Dec; 31(12):1919-24. PMID: 3439802.
      View in: PubMed
    129. Chambers HF, Hackbarth CJ. Effect of NaCl and nafcillin on penicillin-binding protein 2a and heterogeneous expression of methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1987 Dec; 31(12):1982-8. PMID: 3439805.
      View in: PubMed
    130. Sachdeva M, Hackbarth C, Stella FB, Chambers HF. Comparative activity of CGP 31608, nafcillin, cefamandole, imipenem, and vancomycin against methicillin-susceptible and methicillin-resistant staphylococci. Antimicrob Agents Chemother. 1987 Oct; 31(10):1549-52. PMID: 3481245.
      View in: PubMed
    131. Chambers HF, Miller MH. Emergence of resistance to cephalothin and gentamicin during combination therapy for methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J Infect Dis. 1987 Mar; 155(3):581-5. PMID: 3643249.
      View in: PubMed
    132. Carpenter TC, Hackbarth CJ, Chambers HF, Sande MA. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1986 Sep; 30(3):382-4. PMID: 3640590.
      View in: PubMed
    133. Hackbarth CJ, Chambers HF, Sande MA. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother. 1986 Apr; 29(4):611-3. PMID: 3707110.
      View in: PubMed
    134. Chambers HF, Hartman BJ, Tomasz A. Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin. J Clin Invest. 1985 Jul; 76(1):325-31. PMID: 4019783.
      View in: PubMed
    135. Sullam PM, Täuber MG, Hackbarth CJ, Chambers HF, Scott KG, Sande MA. Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1985 May; 27(5):685-7. PMID: 3860185.
      View in: PubMed
    136. Chambers HF, Mills J, Drake TA, Sande MA. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis. 1984 Nov-Dec; 6 Suppl 4:S870-4. PMID: 6522927.
      View in: PubMed
    137. Chambers HF, Sande MA. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984 Jul; 26(1):61-4. PMID: 6236747.
      View in: PubMed
    138. Chambers HF, Hackbarth CJ, Drake TA, Rusnak MG, Sande MA. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro. J Infect Dis. 1984 Jun; 149(6):894-903. PMID: 6564133.
      View in: PubMed
    139. Chambers HF, Korzeniowski OM, Sande MA. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. Medicine (Baltimore). 1983 May; 62(3):170-7. PMID: 6843356.
      View in: PubMed